Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prelude Therapeutics (PRLD) Cash & Current Investments (2023 - 2026)

Prelude Therapeutics' Cash & Current Investments history spans 4 years, with the latest figure at $144.6 million for Q1 2026.

  • On a quarterly basis, Cash & Current Investments rose 40.23% to $144.6 million in Q1 2026 year-over-year; TTM through Mar 2026 was $144.6 million, a 40.23% increase, with the full-year FY2025 number at $103.2 million, down 25.02% from a year prior.
  • Cash & Current Investments hit $144.6 million in Q1 2026 for Prelude Therapeutics, up from $103.2 million in the prior quarter.
  • Over the last five years, Cash & Current Investments for PRLD hit a ceiling of $237.0 million in Q4 2023 and a floor of $58.2 million in Q3 2025.
  • Historically, Cash & Current Investments has averaged $145.6 million across 4 years, with a median of $141.1 million in 2024.
  • Biggest five-year swings in Cash & Current Investments: tumbled 63.09% in 2025 and later skyrocketed 40.23% in 2026.
  • Tracing PRLD's Cash & Current Investments over 4 years: stood at $237.0 million in 2023, then crashed by 41.91% to $137.7 million in 2024, then fell by 25.02% to $103.2 million in 2025, then surged by 40.1% to $144.6 million in 2026.
  • Business Quant data shows Cash & Current Investments for PRLD at $144.6 million in Q1 2026, $103.2 million in Q4 2025, and $58.2 million in Q3 2025.